Talineuren. Neuroprotective Therapy for Control of Parkinson’s Disease Enabled by Nanoparticle Delivery of GM1 Across Blood-brain barrier, observed in All Clinical Trial PD Patients, and with Regenerative Effects Observed in a Subset of PD Patients
Partners: InnoMedica Switzerland AG and Normax Biomed Limited
Principal Investigator: Dr. med. Michael Schüpbach, Parkinson’s Disease Specialist, Neurologist, Neurology Institut in Konolfingen – Switzerland
Project Manager: Dr. Camille Peitsch, R&D Director, InnoMedica.
Business Management: Dr. Stéfan Halbherr, CEO, InnoMedica, Dr. Jonas Zeller, CFO, InnoMedica, Peter A. Jensen, CEO & Chairman, Normax Biomed
Clinical Trials: Talineuren (TLN-1) Clinical Trials for Parkinson’s Disease